Individualizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2015 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from May 21, 2015 to June 30, 2016

Instructions for CME: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. It is best to save your certificate. You will need to click on the “download” button and choose save.

These presentations require Adobe Flash Player.  You can download it here.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Astra Zeneca, Novo Nordisk, and sanofi-aventis US


PLEASE CLICK HERE TO VIEW THE PRESENTATION


PLEASE CLICK HERE TO VIEW THE PRESENTATION IN HTML

PLEASE CLICK HERE FOR EVALUATION and POST-TEST

Description
While the prevalence of diabetes continues to rise, a new generation of treatments has become available in the past few years. Continuing education is needed to educate health care professionals about these agents for treatment of T2DM that are effective in lowering A1C levels, especially in the area of insulin and GLP-1 therapy. There have been many questions in member surveys and past program evaluations about the best practices in regards to the role of insulin and GLP-1 therapy in individualizing the treatment of type 2 diabetes.

Upon Completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of current and emerging therapies, including insulin and GLP-1 therapies, for achieving glycemic and HA1c target goals in types 2 diabetes

  • Individualize treatment goals for patients with T2DM that reflect the degree of hyperglycemia, comorbid conditions, disease duration, and responses to therapy

  • Discuss provider-related and patient-related barriers to use of insulin and GLP-1 therapies in the management of T2DM

  • Examine the importance of customizing A1c goals based on individual patient characteristics

  • Identify patients who are good candidates for GLP-1 or insulin therapy according to current guidelines
     

Faculty: Timothy Reid, MD
Diabetes and Metabolism
Mercy Health System

Disclosure:

Dr. Timothy Reid serves as speaker for Boehringer Ingelheim/Lilly, Janssen, Lilly, Novo Nordisk and sanofi.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
  

This activity is supported by an educational grant from
Astra Zeneca, Novo Nordisk, and sanofi-aventis US

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.